Annovis Bio, Inc. (ANVS) Form 8-K — Oct 30, 2026
$ANVSForm 8-KItems 3.01, 7.01, 9.01Filed Oct 30, 2026, 5:10 PM ET0001104659-26-120732Original filing
Annovis Bio received an NYSE notice on October 29, 2026 that it is out of compliance with continued listing standards, with a 30-day average market cap of approximately $48.4 million and a stockholders' deficit of $(4.3) million as of June 30, 2026. The stock remains listed but will trade with a '.BC' below-criteria designation. Annovis must submit a compliance plan within 45 days; if NYSE rejects it or the company fails the 9-month cure period, suspension and delisting proceedings will be initiated.
Key figures
- Cure period
- 9 months
- Avg market cap 30day
- $48.4 million
- Market cap threshold
- $50 million
- Stockholders deficit
- $(4.3) million
- Plan submission deadline
- 45 days from Notice
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.